Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;91(5):735-736.
doi: 10.1002/ana.26340. Epub 2022 Mar 26.

Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"

Antje Bischof  1   2 , Nico Papinutto  1 , Anisha Keshavan  1 , Anand Rajesh  1 , Gina Kirkish  1 , Xinheng Zhang  1 , Jacob M Mallott  1 , Carlo Asteggiano  1 , Simone Sacco  1 , Tristan J Gundel  1 , Chao Zhao  1 , William A Stern  1 , Eduardo Caverzasi  1 , Yifan Zhou  1 , Refujia Gomez  1 , Nicholas R Ragan  1 , Adam Santaniello  1 , Alyssa H Zhu  1 , Jeremy Juwono  1 , Carolyn J Bevan  1 , Riley M Bove  1 , Elizabeth Crabtree-Hartman  1 , Jeffrey M Gelfand  1 , Douglas S Goodin  1 , Jennifer S Graves  1 , Ari J Green  1 , Jorge R Oksenberg  1 , Emmanuelle Waubant  1 , Michael R Wilson  1 , Scott S Zamvil  1 ; University of California, San Francisco MS-EPIC Team  1 ; Bruce A Cree  1 , Stephen L Hauser  1 , Roland G Henry  1
Affiliations
Comment

Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS"

Antje Bischof et al. Ann Neurol. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following companies that have had financial relationships with authors manufacture disease‐modifying drugs for MS that were mentioned in this study: Bayer Schering, Biogen, EMD Serono, Genentech, Genzyme, F. Hoffmann‐La Roche, Mylan Pharmaceuticals, Novartis, Sanofi, Teva Pharmaceuticals. R.M.B. has received personal compensation for medical legal consulting and for consulting or serving on the advisory boards of F. Hoffmann‐La Roche, Sanofi‐Genzyme, and Novartis. J.M.G. reports consulting fees from Biogen and research support from Genentech. D.S.G. has received research support and given lectures on MS and its treatment that have been sponsored by Biogen Idec, Bayer Schering, Novartis, EMD Serono, Genzyme, and Teva Pharmaceuticals. J.S.G. reports personal fees from Novartis and Genentech and grants from Biogen, and EMD Serono. A.J.G. reports personal fees from Mylan Pharmaceuticals, grants from Novartis, and payments for serving on committees from Biogen and Novartis. E.W. has received research support from Novartis and Roche. M.R.W. receives research support from Roche/Genentech. S.S.Z. has served as a consultant and received honoraria from Biogen Idec, EMD Serono, Genzyme, Novartis, Roche/Genentech, and Teva Pharmaceuticals, and has served on data safety monitoring boards for Teva. B.A.C. has received personal compensation for consulting from Biogen, EMD Serono, and Novartis. R.G.H. received grants from Hoffmann La Roche, and consultancy honoraria from Roche/Genentech, Sanofi/Genzyme, and Novartis. S.L.H. has received travel reimbursement and writing assistance from F. Hoffman‐La Roche and Novartis Pharma. The other authors have nothing to report.

Comment on

  • Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
    Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, Mallott JM, Asteggiano C, Sacco S, Gundel TJ, Zhao C, Stern WA, Caverzasi E, Zhou Y, Gomez R, Ragan NR, Santaniello A, Zhu AH, Juwono J, Bevan CJ, Bove RM, Crabtree E, Gelfand JM, Goodin DS, Graves JS, Green AJ, Oksenberg JR, Waubant E, Wilson MR, Zamvil SS; University of California, San Francisco MS-EPIC Team; Cree BAC, Hauser SL, Henry RG. Bischof A, et al. Ann Neurol. 2022 Feb;91(2):268-281. doi: 10.1002/ana.26281. Epub 2022 Jan 4. Ann Neurol. 2022. PMID: 34878197 Free PMC article.
  • Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS.
    Zeydan B, Rocca MA, Kantarci OH, Filippi M. Zeydan B, et al. Ann Neurol. 2022 May;91(5):734-735. doi: 10.1002/ana.26341. Epub 2022 Mar 17. Ann Neurol. 2022. PMID: 35253269 No abstract available.

References

    1. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi‐array coils and fast spin echo: II. Findings in multiple sclerosis. Neurology 1993;43:2632–2637. - PubMed
    1. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15–19. - PMC - PubMed
    1. Filippi M, Campi A, Colombo B, et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996;243:502–505. - PubMed
    1. Biberacher V, Boucard CC, Schmidt P, et al. Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. Mult Scler 2015;21:875–884. - PubMed
    1. Cawley N, Tur C, Prados F, et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Mult Scler 2018;24:932–941. - PubMed